Efficacy of Abhraka Bhasma in Bronchial Asthma

Comparative clinical efficacy of 30 and 60 Puta Abhraka Bhasma in the management of Tamaka Shawsa (Bronchial Asthmsa)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/08/044596

Enrollment

Registered

2022-08-03

Start date

Unknown

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J453- Mild persistent asthma Health Condition 2: J988- Other specified respiratory disorders

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1.Mild persistant cases of Asthma (as per WHO GINA guideline) with duration of more than 6 months. FEV1 and FEV1/VC below normal. 2.Symptoms/exacerbation (wheeze,cough and breathlessness greater than weekly and less than daily in frequency. 3.Night symptoms more than twice per month but less than once a week.

Exclusion criteria

Exclusion criteria: 1.Age above 60 years and below 18 years 2.Severe complicated cases of Bronchial Asthma like status asthmaticus. 3.Mild intermittent, Moderated persistent, severe persistent to severe Asthma. 4.Patients having uncontrolled diabetes, accelerated hypertension, Chronic and Acute renal failure etc. conditions in which urination is markedly diminished or excessive were excluded. 5.Dyspnoea resulting from other diseases like left ventricular failure, COPD (Chronic Bronchitis, Emphysema), upper respiratory tract obstruction, bronchiectasis, cases of tuberculosis, interstitial lung disease/occupational lung disease, tropical pulmonary eosinophilia & allergic broncho-pulmonary aspergillosis, pneumonia, tuberculosis, lung cancer, lung abscess and other such complicated conditions. 6.Pregnant and lactating mothers. 7.Patients who need Salbutamol inhaler daily. 8.Patients having classical symptoms of Maha, Urdha, Chinna and Kshudraswasa

Design outcomes

Primary

Measure	Time frame
Relief in sign and symptoms like Breathlessness, frequency of episodes etcTimepoint: 02 month	—

Secondary

Measure	Time frame
1.Decrease in the severity of attack 2.Reduction in number of puffs per day 3.Improvement in peak flow rate Asthma control questionnaire, Asthma Test score, GINA assessment of Asthma control, FEV1, Peak expiratiry flow rate and Breath Holding time will be applied to assess secondary outcomesTimepoint: 03 month	—

Countries

India

Contacts

Public ContactBJ Patgiri

Institute of Teaching and Research in Ayurveda

patgiri124@gmail.com9426947438

Outcome results